<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dimercaptosuccinic acid (succimer): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dimercaptosuccinic acid (succimer): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dimercaptosuccinic acid (succimer): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12007" href="/d/html/12007.html" rel="external">see "Dimercaptosuccinic acid (succimer): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12808" href="/d/html/12808.html" rel="external">see "Dimercaptosuccinic acid (succimer): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F223371"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Chemet</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F223387"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidote</li></ul></div>
<div class="block doa drugH1Div" id="F223374"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Consultation with a clinical toxicologist or an expert in the treatment of heavy metal poisoning is highly recommended.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="649653cd-f976-4067-a185-5ba82607ac2f">Arsenic poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Arsenic poisoning (off-label use): </b>Dosing is based on the use of succimer for the treatment of lead poisoning (Howland 2018; Kosnett 2013). Consultation with a clinical toxicologist or poison control center is highly recommended in patients who are being considered for chelation therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 10 mg/kg 3 times daily for 5 days followed by 10 mg/kg twice daily for 14 days (Howland 2018).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ad6c1520-f76f-4866-9ee2-58ecc5033ef3">Lead poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lead poisoning (off-label use):</b> Available guidelines recommend chelation therapy with blood lead levels (BLL) &gt;50 mcg/dL and significant symptoms; chelation therapy may also be indicated for most patients with BLL ≥80 mcg/dL and all patients with BLL ≥100 mcg/dL and/or symptoms (CSTE 2013; Kosnett 2007). Selection of chelating regimen should be made in consultation with a clinical toxicologist or expert in the treatment of heavy metal poisoning.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 10 mg/kg 3 times daily for 5 days followed by 10 mg/kg twice daily for 14 days (Howland 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Treatment courses may be repeated, but 2-week intervals between courses is generally recommended because lead re-equilibrates between the extravascular storage sites (eg, bone) and the vascular compartment. High initial blood lead levels (eg, &gt;100 mcg/dL) or presence of lead encephalopathy may indicate the need for more prompt retreatment (Howland 2018); consultation with a clinical toxicologist or poison control center is highly recommended.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b7c73db4-de24-40d4-9038-49fb272e8fb1">Mercury poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mercury poisoning (off-label use): </b>Dosing is based on the use of succimer for the treatment of lead poisoning (Howland 2018; Kosnett 2013). Consultation with a clinical toxicologist or poison control center is highly recommended in patients who are being considered for chelation therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 10 mg/kg 3 times daily for 5 days followed by 10 mg/kg twice daily for 14 days (Howland 2018).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990241"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Succimer is dialyzable; however, the lead chelates are not.</p></div>
<div class="block doha drugH1Div" id="F50987372"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; has not been studied. More frequent monitoring of serum transaminases may be required in patients with a history of liver disease due to the risk of transient increases.</p></div>
<div class="block dot drugH1Div" id="F20989270"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">ANC &lt;1200 mm<sup>3</sup>:  The manufacturer recommends withholding treatment; treatment may be cautiously resumed when ANC returns to baseline or &gt;1500/mm<sup>3</sup>. Consultation with a medical toxicologist to determine the risk versus benefit of withholding treatment is recommended.</p></div>
<div class="block doe drugH1Div" id="F223375"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F223383"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12808" href="/d/html/12808.html" rel="external">see "Dimercaptosuccinic acid (succimer): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Consultation with a clinical toxicologist, poison control center, or an expert in the treatment of heavy metal poisoning is highly recommended. Dosing is presented in both mg/kg and mg/<b>m<sup>2</sup></b>; use caution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="649653cd-f976-4067-a185-5ba82607ac2f">Arsenic poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Arsenic poisoning: </b>Limited data available: <b>Note:</b> Dosing is based on the use of succimer for the treatment of lead poisoning (Howland 2018; Kosnett 2013). Experts recommend dosing for children &lt;5 years of age should be based on body surface area (AAP 2005; Howland 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;5 years: Oral: 350 mg/<b>m<sup>2</sup></b>/dose every 8 hours for 5 days followed by 350 mg/<b>m<sup>2</sup></b>/dose every 12 hours for 14 days; maximum dose: 500 mg/dose; round dose to the nearest 100 mg (Howland 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents: Oral: 10 mg/kg/dose or 350 mg/<b>m<sup>2</sup></b>/dose every 8 hours for 5 days followed by 10 mg/kg/dose or 350 mg/<b>m<sup>2</sup></b>/dose every 12 hours for 14 days; round dose to the nearest 100 mg; maximum dose: 500 mg/dose (Howland 2018).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3f9b633a-968e-4420-aaa9-e06d3c9959bd">Lead poisoning, mild and asymptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lead poisoning, mild and asymptomatic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For the treatment of high blood lead levels (BLL) in children, the CDC recommends chelation treatment when BLL &gt;45 mcg/dL (ACCLPP 2012; CDC 2002). The AAP recommends succimer as the drug used for initial management in asymptomatic children when BLL &gt;45 mcg/dL and &lt;70 mcg/dL; children with BLL ≥70 mcg/dL or symptomatic lead poisoning should be treated with parenteral agents (AAP [Shenoi 2020]; Calello 2018). Selection of chelating regimen should be made in consultation with a clinical toxicologist or expert in the treatment of heavy metal poisoning.</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: 10 mg/kg/dose or 350 mg/<b>m<sup>2</sup></b>/dose every 8 hours for 5 days followed by 10 mg/kg/dose or 350 mg/<b>m<sup>2</sup></b>/dose every 12 hours for 14 days; maximum dose: 500 mg/dose; maximum daily dose: 1,500 mg/<b>day</b>. <b>Note:</b> Some experts recommend dosing for children &lt;5 years of age should be based on body surface area (AAP 2005; Howland 2018); round doses to the nearest 100 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Treatment courses may be repeated, but 2-week intervals between courses is generally recommended because lead re-equilibrates between the extravascular storage sites (eg, bone) and the vascular compartment (Calello 2018).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b7c73db4-de24-40d4-9038-49fb272e8fb1">Mercury poisoning</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mercury poisoning:</b> Limited data available: <b>Note:</b> Dosing is based on the use of succimer for the treatment of lead poisoning (Howland 2018; Kosnett 2013). Experts recommend dosing for children &lt;5 years of age should be based on body surface area (AAP 2005; Howland 2018); round doses to the nearest 100 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;5 years: Oral: 350 mg/<b>m<sup>2</sup></b>/dose every 8 hours for 5 days followed by 350 mg/<b>m<sup>2</sup></b>/dose every 12 hours for 14 days; maximum dose: 500 mg/dose; round dose to the nearest 100 mg (Howland 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥5 years and Adolescents: Oral: 10 mg/kg/dose or 350 mg/<b>m<sup>2</sup></b>/dose every 8 hours for 5 days followed by 10 mg/kg/dose or 350 mg/<b>m<sup>2</sup></b>/dose every 12 hours for 14 days; maximum dose: 500 mg/dose.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> Children and Adolescents: ANC &lt;1,200/mm<sup>3</sup>: The manufacturer recommends withholding treatment; treatment may be cautiously resumed when ANC returns to baseline or &gt;1,500/mm<sup>3</sup>. Consultation with a clinical toxicologist to determine the risk versus benefit of withholding treatment is recommended.</p></div>
<div class="block dorp drugH1Div" id="F51160269"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children and Adolescents: There are no dosage adjustments in the manufacturer's labeling; use with caution and monitor closely. Succimer is dialyzable; however, the lead chelates are not.</p></div>
<div class="block dohp drugH1Div" id="F51160270"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children and Adolescents: There are no dosage adjustments in the manufacturer's labeling; has not been studied. More frequent monitoring of serum transaminases may be required in patients with a history of liver disease due to the risk of transient increases.</p></div>
<div class="block adr drugH1Div" id="F223348"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiac arrhythmia (adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (6% to 10%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Chills, dizziness, drowsiness, fatigue, flank pain, headache, heavy headedness, metallic taste, paresthesia, sensorimotor neuropathy</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Mucocutaneous eruptions, papular rash, pruritus, skin rash, vesicular eruption (mucocutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased serum cholesterol</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, decreased appetite, diarrhea, hemorrhoids, loose stools, nausea, sore throat, stomach pain, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Decreased urine output, difficulty in micturition, proteinuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia, neutropenia, quantitative disorders of platelets (increase)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alkaline phosphatase</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Candidiasis, common cold, herpetic lesion</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain, knee pain, lower extremity pain, rib pain</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cloudy vision (cloudy film in eye), watery eyes</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Blockage of external ear, otitis media</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, flu-like symptoms, nasal congestion, rhinorrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Angioedema, hypersensitivity reaction (especially with retreatment), urticaria</p></div>
<div class="block coi drugH1Div" id="F223361"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to succimer or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F223346"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: Mild to moderate neutropenia has been reported; evaluate CBC with differential at baseline, weekly during treatment, and immediately upon the development of any sign of infection. The manufacturer recommends withholding treatment for ANC &lt;1,200/mm<sup>3</sup>; treatment may be cautiously resumed when ANC returns to baseline or &gt;1,500/mm<sup>3</sup>. Consultation with a clinical toxicologist to determine the risk versus benefit of withholding treatment is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Transient elevations in serum transaminases have been reported. Evaluate serum transaminases at baseline and weekly during treatment; more frequent monitoring may be required in patients with a history of liver disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Monitor for the development of allergic or other mucocutaneous reactions. A reversible mucocutaneous vesicular eruption of the oral mucosa, external urethral meatus, or perianal area has been reported (rarely).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Encephalopathy: Succimer does not cross blood-brain barrier and should not be used to treat encephalopathy associated with lead toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lead poisoning: Investigate, identify, and remove sources of lead exposure prior to treatment; do not permit patients to reenter the contaminated environment until lead abatement has been completed. Consultation with a clinical toxicologist or an expert in the treatment of heavy metal poisoning is highly recommended before initiating chelation therapy. Succimer is not used to prevent lead poisoning. A rebound rise in serum lead levels may occur after treatment as lead is released from storage sites into blood. The severity of rebound may guide the frequency of future monitoring and the need for additional chelation therapy. In a small prospective, randomized, open-label trial, succimer was shown to improve clinical signs and symptoms of lead poisoning and to reduce blood lead levels more effectively than edetate calcium disodium (Sakthithasan 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment. Succimer is dialyzable; however, the lead chelates are not.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hydration: Adequate hydration should be maintained during therapy.</p></div>
<div class="block foc drugH1Div" id="F223356"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Chemet: 100 mg</p></div>
<div class="block geq drugH1Div" id="F223342"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323897"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Chemet Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $26.44</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F5168980"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">If unable to swallow whole, capsule may be separated and contents sprinkled on a small amount of soft food, or the contents placed on a spoon and administered followed by fruit drink.</p></div>
<div class="block admp drugH1Div" id="F52613883"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Ensure adequate patient hydration; for patients who cannot swallow the capsule whole, immediately prior to administration open the capsule and sprinkle the medicated beads into a small amount of juice or on a small amount of apple sauce, ice cream, or soft food or placed on a spoon and followed with fruit drink to mask the odor (Howland 2018).</p></div>
<div class="block use drugH1Div" id="F223357"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Lead poisoning:</b> Treatment of lead poisoning in children with blood lead levels &gt;45 mcg/dL.</p></div>
<div class="block off-label drugH1Div" id="F25470676"><span class="drugH1">Use: Off-Label: Adult</span><p>Lead poisoning; Mercury poisoning; Arsenic poisoning</p></div>
<div class="block cyt drugH1Div" id="F13300085"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6223110"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F6165840"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Lead poisoning: Lead is known to cross the placenta in amounts related to maternal plasma levels. Prenatal lead exposure may be associated with adverse events such as spontaneous abortion, preterm delivery, decreased birth weight, and impaired neurodevelopment. Some adverse outcomes may occur with maternal blood lead levels &lt;10 mcg/dL. In addition, pregnant women exposed to lead may have an increased risk of gestational hypertension. Consider chelation therapy in pregnant women with confirmed blood lead levels ≥45 mcg/dL (pregnant women with blood lead levels ≥70 mcg/dL should be considered for chelation regardless of trimester); consultation with experts in lead poisoning and high-risk pregnancy is recommended. Encephalopathic pregnant women should be chelated regardless of trimester (CDC 2010).</p></div>
<div class="block brc drugH1Div" id="F6165842"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if succimer is excreted in breast milk. When used for the treatment of lead poisoning, the amount of lead in breast milk may range from 0.6% to 3% of the maternal serum concentration. Women with confirmed blood lead levels ≥40 mcg/dL should not initiate breastfeeding; pumping and discarding breast milk is recommended until blood lead levels are &lt;40 mcg/dL, at which point breastfeeding may resume (CDC 2010). Calcium supplementation may reduce the amount of lead in breast milk.</p></div>
<div class="block mop drugH1Div" id="F223354"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood lead levels (baseline and 7 to 21 days after completing chelation therapy); serum transaminases (baseline and weekly during treatment; may require more frequent monitoring in patients with a history of liver disease), CBC with differential and platelets (baseline, and weekly during treatment); hemoglobin or hematocrit, iron status, free erythrocyte protoporphyrin or zinc protoporphyrin; neurodevelopmental changes.</p></div>
<div class="block pha drugH1Div" id="F223345"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Succimer is an analog of dimercaprol. It forms water soluble chelates with heavy metals which are subsequently excreted renally. Succimer binds heavy metals; however, the chemical form of these chelates is not known.</p></div>
<div class="block phk drugH1Div" id="F223360"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid but incomplete</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Primarily extracellular (Aposhian 1992)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;95% primarily to albumin (Aposhian 1992)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Rapidly and extensively to mixed succimer cysteine disulfides</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~3 hours (Aposhian 1992)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: ~1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~25%) with peak urinary excretion between 2 to 4 hours (90% as mixed succimer-cysteine disulfide conjugates, 10% as unchanged drug); feces (as unabsorbed drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038833"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Succicaptal</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Chemet</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Succicaptal</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Succicaptal</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Succicaptal</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Succicaptal</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Succicaptal</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Chemet</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Chemet</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Advisory Committee on Childhood Lead Poisoning Prevention (ACCLPP). Low-level lead exposure harms children: A renewed call for primary intervention. January 4, 2012. Available at <a href="https://www.cdc.gov/nceh/lead/acclpp/final_document_030712.pdf" target="_blank">http://www.cdc.gov/nceh/lead/acclpp/final_document_030712.pdf</a> . Last accessed on March 17, 2017)</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ATSDR2014a">
<a name="ATSDR2014a"></a>Agency for Toxic Substances &amp; Disease Registry (ATSDR). Medical management guidelines for arsenic (As) and inorganic arsenic compounds. 2014a. Available at: <a href="https://www.atsdr.cdc.gov/MHMI/mmg2.pdf" target="_blank">https://www.atsdr.cdc.gov/MHMI/mmg2.pdf</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ATSDR2014b">
<a name="ATSDR2014b"></a>Agency for Toxic Substances &amp; Disease Registry (ATSDR). Medical management guidelines for mercury (Hg). 2014b. Available at: <a href="https://www.atsdr.cdc.gov/MHMI/mmg46.pdf" target="_blank">https://www.atsdr.cdc.gov/MHMI/mmg46.pdf</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16199720">
<a name="16199720"></a>American Academy of Pediatrics Committee on Environmental Health. Lead exposure in children: prevention, detection, and management. <i>Pediatrics</i>. 2005;116(4):1036-1046. doi:10.1542/peds.2005-1947<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/16199720/pubmed" id="16199720" target="_blank">16199720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11749497">
<a name="11749497"></a>Andersen O. Principles and recent developments in chelation treatment of metal intoxication. <i>Chem Rev</i>. 1999;99(9):2683-2710.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/11749497/pubmed" id="11749497" target="_blank">11749497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1331491">
<a name="1331491"></a>Aposhian HV, Maiorino RM, Rivera M, et al, “Human Studies With the Chelating Agents, DMPS and DMSA,” <i>Clin Toxicol</i>, 1992, 30(4):505-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/1331491/pubmed" id="1331491" target="_blank">1331491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19663612">
<a name="19663612"></a>Bradberry S and Vale A, "Dimercaptosuccinic Acid (Succimer; DMSA) in Inorganic Lead Poisoning," <i>Clin Toxicol (Phila)</i>, 2009, 47(7):617-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/19663612/pubmed" id="19663612" target="_blank">19663612</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Calello DP, Henretig FM. Lead. In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. McGraw-Hill; 2018: 1292-1308.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC), <i>Guidelines for the Identification and Management of Lead Exposure in Pregnant and Lactating Women</i>, Atlanta: CDC; 2010.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control and Prevention (CDC), <i>Managing Elevated Blood Lead Levels Among Young Children: Recommendations from the Advisory Committee on Childhood Lead Poisoning Prevention</i>, Atlanta: CDC; 2002.</div>
</li>
<li>
<div class="reference">
                  Chemet (succimer) [prescribing information]. Lebanon, NJ: Recordati Rare Diseases Inc; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21649453">
<a name="21649453"></a>Crinnion WJ, "EDTA Redistribution of Lead and Cadmium into Soft Tissues in a Human With a High Lead Burden: Should DMSA Always be used to Follow EDTA in Such Cases?" <i>Alt Med Rev</i>, 2011, 16(2):109-112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/21649453/pubmed" id="21649453" target="_blank">21649453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CSTE.2013">
<a name="CSTE.2013"></a>Council of State and Territorial Epidemiologists (CSTE). Management guidelines for blood lead levels in adults. <a href="https://dhhs.ne.gov/Lead%20Documents/Adult-Lead-Management-Guidelines.pdf" target="_blank">https://dhhs.ne.gov/Lead%20Documents/Adult-Lead-Management-Guidelines.pdf</a>. Published June 12, 2013. Accessed February 14, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8040783">
<a name="8040783"></a>Dart RC, Hurlburt KM, Maiorino RM, et al, “Pharmacokinetics of Meso-2,3-Dimercaptosuccinic Acid in Patients With Lead Poisoning and in Healthy Adults,” <i>J Pediatr</i>, 1994, 125(2):309-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/8040783/pubmed" id="8040783" target="_blank">8040783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17453878">
<a name="17453878"></a>Drasch G, Boese-O'Reilly S, Illig S. Increase of renal excretion of organo-mercury compounds like methylmercury by DMPS (2,3-dimercapto-1-propanesulfonic acid, dimaval). <i>Clin Toxicol (Phila)</i>. 2007;45(3):266-269.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/17453878/pubmed" id="17453878" target="_blank">17453878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11285436">
<a name="11285436"></a>Gardella C, “Lead Exposure in Pregnancy: A Review of the Literature and Argument for Routine Prenatal Screening,” <i>Obstet Gynecol Surv</i>, 2001, 56(4):231-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/11285436/pubmed" id="11285436" target="_blank">11285436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17189579">
<a name="17189579"></a>Gracia RC and Snodgrass WR, “Lead Toxicity and Chelation Therapy,” <i>Am J Health Syst Pharm</i>, 2007, 64(1):45-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/17189579/pubmed" id="17189579" target="_blank">17189579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Howland.2018">
<a name="Howland.2018"></a>Howland MA. Antidotes in depth: succimer (2,3-dimercaptosuccinic acid) and DMPS (2,3-dimercapto-1-propanesulfonic acid). In: Nelson LS, Howland MA, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. McGraw-Hill; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24178900">
<a name="24178900"></a>Kosnett MJ. The role of chelation in the treatment of arsenic and mercury poisoning. <i>J Med Toxicol</i>. 2013;9(4):347-354. doi:10.1007/s13181-013-0344-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/24178900/pubmed" id="24178900" target="_blank">24178900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17431500">
<a name="17431500"></a>Kosnett MJ, Wedeen RP, Rothenberg SJ, et al. Recommendations for medical management of adult lead exposure. <i>Environ Health Perspect</i>. 2007;115(3):463-471. doi:10.1289/ehp.9784<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/17431500/pubmed" id="17431500" target="_blank">17431500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1663439">
<a name="1663439"></a>Mann KV and Travers JD, “Succimer, An Oral Lead Chelator,” <i>Clin Pharm</i>, 1991, 10(12):914-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/1663439/pubmed" id="1663439" target="_blank">1663439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29889577">
<a name="29889577"></a>Sakthithasan K, Lévy P, Poupon J, Garnier R. A comparative study of edetate calcium disodium and dimercaptosuccinic acid in the treatment of lead poisoning in adults. <i>Clin Toxicol (Phila)</i>. 2018;56(11):1143-1149. doi:10.1080/15563650.2018.1478424<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/29889577/pubmed" id="29889577" target="_blank">29889577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs Used to Treat Pediatric Emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dimercaptosuccinic-acid-succimer-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9102 Version 136.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
